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Abstract With the ever-changing landscape of transla-
tional research, the medical device and pharmaceutical
industries increasingly license technologies with the added
value of clinical and/or pre-clinical data rather than those
in earlier stages of development. Universities have the
potential to fill the gap in product development from aca-
demic laboratories through enhanced student training and
increased implementation of some development and man-
ufacturing activities that are traditionally found only in the
private sector. A development roadmap is described from
initial product feasibility through commercialization in the
context of efficient development practices. The specific
challenges in the design and development of biomaterial-
based medical devices are described in the context of this
development path with an emphasis on unique challenges
for academic laboratories.
1 The Changing Landscape of Translational Research
in Medical Devices and Drugs
Translation of novel medical technologies from academic
laboratories to the market has undergone a major shift over
the past several years. Changes in this landscape have
moved commercial licensing and intellectual property
transfer deeper into the product development timeline. This
has a profound implication for the role of academic insti-
tutions and researchers. Medical device and pharmaceutical
industries are experiencing increased regulatory scrutiny
with initiatives focused on comparative efficacy research
and the sentinel initiative, which bolsters increased product
oversight throughout development [1]. These initiatives are
adding value to potential products by ensuring greater
consumer safety. However, they also strain this increas-
ingly cost-sensitive and risk-averse industry. The devel-
opment path for an idea to a medical product is typically
based on multiple factors including market trends, ten-
dencies of the industry, capitalization, and regulatory
requirements [2, 3]. Figure 1 highlights the critical path in
the development of an idea to a product and this includes:
invention and patent application, basic research, product
design and development, manufacturing, pre-clinical and
clinical testing, regulatory review, and commercialization.
Throughout this path, windows of opportunity exist for
licensing so that the inventor does not carry the technology
entirely up to and through product commercialization.
Licensing refers to the process in which the owner of a
patent or copyright grants another entity the rights to use
the patent and in return receives royalties on product sales
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or other compensation. In the past, companies have been
willing to license technology while it was still in the
research phase or early product design. However, in recent
years, companies and venture capital groups have focused
on reducing their risks by requiring pre-clinical data and
may even desire human clinical data prior to investment.
Value-added pieces such as design documentation, manu-
facturing protocols, or clinical data often demonstrate that
reduced risk. Therefore, the pressure is on the inventors to
engage in product development through manufacturing and
clinical assessment.
The shift in research goals and development efforts prior
to licensing begs two key questions: (1) who can/should
fund the process of carrying inventions through manufac-
turing, regulatory filing, pre-clinical and clinical safety
trials, and (2) who is best equipped to do so? Ideas that
begin in larger corporations often start with the capital to
usher inventions through these processes. But in many
industries, discovery and development efforts are consis-
tently in the risk of being eliminated from the operational
budget. Funding agencies for academia typically support
mechanistic and hypothesis-driven research (i.e., high
commercial risk) so have not been traditionally involved in
activities such as product manufacturing or pre-clinical or
clinical trials. However, major granting agencies have
recently initiated pilot programs, such as the Clinical and
Translational Science Awards (CTSA) and the National
Center for Advancing Translational Sciences of the
National Institutes of Health (NIH) in the US, to support
translational efforts in academia in order to encourage
newer technologies to enter the market. Universities serve a
key role in society by educating students in nearly all areas
of study and also facilitating research and training in
almost as many disciplines. However, applied engineering,
basic science research, and medical practice are not tradi-
tionally grouped together to confront the challenges of
translational medicine. Manufacturing, regulatory filing,
and clinical trials require novel partnerships across these
disciplines. Additionally, expertise in manufacturing and
regulatory filing is often acquired through on-the-job
training in industrial or corporate settings. Therefore,
bringing these skills into academia requires partnership
with industry experts and recruitment of faculty with
industry-focused experience. But then the overall educa-
tional mission would need to be reassessed. Graduate
training in physical and biological sciences traditionally
involves formulating testable hypotheses then evaluating
through rigorous experimental design. To modify this
training paradigm by including goal-oriented product
development may be controversial. But this dilemma does
demonstrate the challenge of finding a new balance
amongst effective student training for the workforce,
societal needs, and funding trends.
2 Key Product Development Challenges in Academia
Organization and management are essential in device
development, because these initiatives require larger teams
of highly diversified individuals. However, highly struc-
tured and regulated processes, which include major strat-
egies for product and possibly business development, are
not common in academic laboratories. The following
resources may be used to help guide scientists and engi-
neers who are new to development. Piezsch et al. [4]
describe a useful structure for managing device develop-
ment from concept selection to post-market surveillance in
accordance with regulations imposed by the International
Fig. 1 General development
path for translational medicine
with a shift in the window of
opportunity for licensing
intellectual property
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Standards Organization and the United States Food and
Drug Administration. This development guide details five
sequential phases: (1) Initiation/opportunity and risk anal-
ysis, (2) formulation/concept and feasibility phase, (3)
design and development/verification & validation phase,
(4) final validation/product launch preparation phase, (5)
and product launch and post-launch assessment. Addi-
tionally, multiple strategies for intellectual property,
research and development, regulatory filing, and clinical
approaches have been effectively summarized by Zenios,
Makower, and Yock [5]. These published resources may be
used to help academic scientists and engineers manage and
organize key steps of development. Another component in
product development is cost analysis of new medical
device and/or drug technology and the efficacy thereof in
the eventual clinical success. There are multiple examples
in drugs and devices where the significant increase in cost
correlated to only a marginal increase in extended life
expectancy as a success benchmark. While this is not often
considered in basic science laboratories, such cost-effective
analyses regularly drive the decision making process in
product development in the private sector.
Material synthesis and manufacturing introduce many
technical design challenges that are often unfamiliar to
academic researchers but are part of the critical path in
product development. Some of these include scale-up,
equipment limitations, sterile processes, and endotoxin
management. These challenges play a major role in plan-
ning and budgeting as well. Understanding the complexity
of these challenges can assist in process design toward a
greater success in navigating the product development
process. For example, synthesis scales in product devel-
opment can be multiple orders of magnitude larger than
that required for most basic research studies. Efficient
scale-up in production requires incremental increases in the
amount of starting products for each synthesis then fol-
lowed by extensive characterization to confirm verification
parameters. This approach may help to identify issues
related to supplier quantities, reagent efficiencies, and/or
equipment limitations. Targeted cost-benefit analysis can
help to determine the utility of either scaling-up synthetic
equipment or dedicating more labor time. Assessing
development goals may also inform scaling activities. For
example, more attention may be paid to process efficiency
if the goal is to build a company rather than out-licensing
to increase process efficiency. Contract manufacturing
organizations (CMO) may provide assistance to overcome
equipment limitations and scale-up issues, particularly
when good manufacturing practice (GMP) manufacturing
and packaging conditions are required. Identifying a suit-
able partner amongst the myriad CMOs can be a daunting
effort. A prioritized list of CMO criteria would help to
hone in on the ideal partner. Considerations may include:
specialized equipment capabilities for the material in
development, willingness to accommodate the scale of the
project, assist in process development including workflow
and packaging, analytical capability which can assist in
product verification, downstream packaging and labeling
that require a sterile environment with GMP validation that
are rare in academic settings, cost, effective communica-
tion and transportation.
Sterility is one of the most critical considerations for
patient safety and product success. Although considered by
academic researchers, it may not be at the level and rigor
required by regulatory agencies. Sterilization can be dis-
ruptive to synthetic processes or can modify the final
product to an extent that inhibits its end-stage use. Con-
sidering sterilization very early on in the process design
would minimize these disruptions. Filtration, electron-
beam treatment, k-irradiation treatment, or ethylene oxide
exposure are all common techniques which can be built
into the manufacturing process. Microbial content alone is
not the only immunologic threat to patients. Microbial
endotoxin levels must be closely monitored and mitigated
to reduce the potential for untoward device-related immune
response and complications. Regulatory agencies have
strict guidelines for this. Animal-derived materials such as
collagen are notorious for high endotoxin content that is
difficult to remove.
The aforementioned topics are starting to be incorpo-
rated into classroom education at undergraduate and
graduate levels in institutions such as Stanford (http://
www.stanford.edu/group/biodesign/bme-idea//meetings/
10-11/) and University of Wisconsin—Madison. This trend
is expected to increase as universities take on a more active
role in medical product development.
3 Conclusion
The licensing of intellectual property in medical devices
and drugs is occurring much later in the product develop-
ment path. Universities are positioned to tackle challenges
in product development such as manufacturing, pre-clinical
and clinical safety testing as a part of the educational and
research mission. Appreciation and understanding of the
basic critical path of initiation, formulation, design and
development, final validation, and product launch should
be incorporated into undergraduate and graduate education.
Understanding key challenges in this development-to-
product process will also help universities in assessing its
research mission, funding priority, and patent portfolio.
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